Creation of the Biobank Related to Eye Disease
BioBank
1 other identifier
observational
669
1 country
1
Brief Summary
The purpose of this study is to develop a BioBank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2009
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 10, 2010
CompletedFirst Posted
Study publicly available on registry
November 15, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 4, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 4, 2017
CompletedJanuary 11, 2018
January 1, 2018
8.5 years
November 10, 2010
January 10, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studies
Biobanks can be used for numberous discovery applications such as: identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization and validation of biomarkers that are predictive of disease and treatment.
Eligibility Criteria
All pediatric and adult patients (age 0-99)who are being seen in the eye Dr. office and or having eye surgery
You may not qualify if:
- Patients who are cognitively impaired and are not able to verbalize understanding of the risks/benefits.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kimberly Drenserlead
- Vision Research Foundationcollaborator
Study Sites (1)
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
Biospecimen
blood, urine other body fluids (i.e. vitreous)
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Kimberly Drenser, MD, PhD
Associated Retinal Consultants, P.C.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- M.D, Ph.D.
Study Record Dates
First Submitted
November 10, 2010
First Posted
November 15, 2010
Study Start
June 1, 2009
Primary Completion
December 4, 2017
Study Completion
December 4, 2017
Last Updated
January 11, 2018
Record last verified: 2018-01
Data Sharing
- IPD Sharing
- Will not share
No plan to share at this time